- Home
- FNV vs TAK Comparison
FNV vs TAK Comparison
Compare FNV & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FNV | TAK |
|---|---|---|
| Founded | 1986 | 1781 |
| Country | Canada | Japan |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1B | 43.3B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | FNV | TAK |
|---|---|---|
| Price | $217.53 | $15.66 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $228.63 | N/A |
| AVG Volume (30 Days) | 691.6K | ★ 2.6M |
| Earning Date | 11-03-2025 | 01-29-2026 |
| Dividend Yield | 0.70% | ★ 3.39% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.77 | 0.14 |
| Revenue | $1,531,400,000.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $58.95 | N/A |
| Revenue Next Year | $27.97 | $0.47 |
| P/E Ratio | ★ $45.25 | $111.82 |
| Revenue Growth | ★ 40.88 | N/A |
| 52 Week Low | $115.79 | $12.80 |
| 52 Week High | $225.64 | $15.69 |
Technical Indicators
Market Signals| Indicator | FNV | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 78.41 |
| Support Level | $212.26 | $14.43 |
| Resistance Level | $217.50 | $14.66 |
| Average True Range (ATR) | 5.32 | 0.17 |
| MACD | 0.63 | 0.13 |
| Stochastic Oscillator | 86.78 | 99.66 |
Price Performance
Historical ComparisonAbout FNV Franco-Nevada Corporation
Franco-Nevada Corp is a precious-metals-focused royalty and investment company. The company owns a diversified portfolio of precious metals and royalty streams, which is actively managed to generate the bulk of its revenue from gold, silver, and platinum. The company does not operate mines, develop projects, or conduct exploration. The company's short-term financial performance is linked to the price of commodities and the amount of production from its portfolio of producing assets. Its long-term performance is affected by the availability of exploration and development capital. The company holds a portfolio of assets, diversified by commodity, revenue type, and stage of a project.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.